Evaluation of the Effects of Nobiletin on Toll-Like Receptor 3 Signaling Pathways in Prostate Cancer In Vitro

References

• Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335–76. doi:10.1146/annurev.immunol.21.120601.141126
   PubMed Web of Science ®Google Scholar
• Rakoff Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer. 2009;9(1):57–63. doi:10.1038/nrc2541
   PubMed Web of Science ®Google Scholar
• Salaun B, Romero P, Lebecque S. Toll-like receptors' two-edged sword: when immunity meets apoptosis. Eur J Immunol. 2007;37(12):3311–8. doi:10.1002/eji.200737744
   PubMed Web of Science ®Google Scholar
• Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol. 2015;33:257–90. doi:10.1146/annurev-immunol-032414-112240
   PubMed Web of Science ®Google Scholar
• Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev. 2009;227(1):75–86. doi:10.1111/j.1600-065X.2008.00737.x
   PubMed Web of Science ®Google Scholar
• Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol. 2006;176(8):4894–0. doi:10.4049/jimmunol.176.8.4894
   PubMed Web of Science ®Google Scholar
• Salaun B, Lebecque S, Matikainen S, Rimoldi D, Romero P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy? Clin Cancer Res. 2007;13(15 Pt 1):4565–74. doi:10.1158/1078-0432.CCR-07-0274
   PubMed Web of Science ®Google Scholar
• Friboulet L, Pioche-Durieu C, Rodriguez S, Valent A, Souquère S, Ripoche H, Khabir A, Tsao SW, Bosq J, Lo KW, et al. Recurrent overexpression of c-IAP2 in EBV-associated nasopharyngeal carcinomas: critical role in resistance to Toll-like receptor 3-mediated apoptosis. Neoplasia. 2008;10(11):1183–94. doi:10.1593/neo.08590
   PubMed Web of Science ®Google Scholar
• Morikawa T, Sugiyama A, Kume H, Ota S, Kashima T, Tomita K, Kitamura T, Kodama T, Fukayama M, Aburatani H, et al. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clin Cancer Res. 2007;13(19):5703–9. doi:10.1158/1078-0432.CCR-07-0603
   PubMed Web of Science ®Google Scholar
• Park J-H, Jeon D-I, Yoon H-E, Kwon S-M, Kim S-A, Ahn S-G, Yoon J-H. Poly I:C inhibits cell proliferation and enhances the growth inhibitory effect of paclitaxel in oral sqaumous cell carcinoma. Acta Odontol Scand. 2012;70(3):241–5. doi:10.3109/00016357.2011.640278
   PubMed Web of Science ®Google Scholar
• Kang S, Fernandes-Alnemri T, Rogers C, Mayes L, Wang Y, Dillon C, Roback L, Kaiser W, Oberst A, Sagara J, et al. Caspase-8 scaffolding function and MLKL regulate NLRP3 inflammasome activation downstream of TLR3. Nat Commun. 2015;6:7515: doi:10.1038/ncomms8515
   PubMed Web of Science ®Google Scholar
• Rydberg C, Månsson A, Uddman R, Riesbeck K, Cardell LO. Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas. Immunology. 2009;128(1 Suppl):e600–e611. doi:10.1111/j.1365-2567.2008.03041.x
   PubMed Web of Science ®Google Scholar
• Paone A, Starace D, Galli R, Padula F, De Cesaris P, Filippini A, Ziparo E, Riccioli A. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis. 2008;29(7):1334–42. doi:10.1093/carcin/bgn149
   PubMed Web of Science ®Google Scholar
• Gambara G, Desideri M, Stoppacciaro A, Padula F, De Cesaris P, Starace D, Tubaro A, Del Bufalo D, Filippini A, Ziparo E, et al. TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo. J Cell Mol Med. 2015;19(2):327–39. doi:10.1111/jcmm.12379
   PubMed Web of Science ®Google Scholar
• Fleshner N, Zlotta AR. Prostate cancer prevention: past, present, and future. Cancer. 2007;110(9):1889–99. doi:10.1002/cncr.23009
   PubMed Web of Science ®Google Scholar
• Schulz WA, Alexa A, Jung V, Hader C, Hoffmann MJ, Yamanaka M, Fritzsche S, Wlazlinski A, Müller M, Lengauer T, et al. Factor interaction analysis for chromosome 8 and DNA methylation alterations highlights innate immune response suppression and cytoskeletal changes in prostate cancer. Mol Cancer. 2007;6:14. doi:10.1186/1476-4598-6-14
   PubMed Web of Science ®Google Scholar
• Harashima N, Inao T, Imamura R, Okano S, Suda T, Harada M. Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells. Cancer Immunol Immunother. 2012;61(5):667–76. doi:10.1007/s00262-011-1132-1
   PubMed Web of Science ®Google Scholar
• Sun J, Wiklund F, Zheng SL, Chang B, Bälter K, Li L, Johansson J-E, Li G, Adami H-O, Liu W, et al. Sequence variants in toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk. J Natl Cancer Inst. 2005;97(7):525–32. doi:10.1093/jnci/dji070
   PubMedGoogle Scholar
• Meiyanto E, Hermawan A. Anindyajati  Natural products for cancer-targeted therapy: citrus flavonoids as potent chemopreventive agents. Asian Pac J Cancer Prev. 2012;13:427–36. doi:10.7314/apjcp.2012.13.2.427
   PubMed Web of Science ®Google Scholar
• Yang C, Wang X, Lu G, Picinich S. Cancer prevention by tea: animal studies, molecular mechanisms and human n relevance. Nat Rev Cancer. 2009;9(6):429–39. doi:10.1038/nrc2641
   PubMed Web of Science ®Google Scholar
• McCann S, Freudenheim J, Marshall J, Saxon G. Risk of human ovarian cancer is related to dietary intake of selected nutrients, phytochemicals and food groups. J Nutr. 2003;133(6):1937–42. doi:10.1093/jn/133.6.1937
   PubMed Web of Science ®Google Scholar
• Guney Eskiler G, Deveci AO, Bilir C, Kaleli S. Synergistic Effects of Nobiletin and Sorafenib Combination on Metastatic Prostate Cancer Cells. Nutr Cancer. 2019;71(8):1299–312.
   PubMed Web of Science ®Google Scholar
• Güney Eskiler G, Deveci Ozkan A, Kaleli S. Determination of cytotoxic and apoptotic effects of nobiletin on metastatic prostate cancer. Sakarya Med J. 2018;8(4):766–74.
   Google Scholar
• Xiao J, Capanoglu E, Jassbi AR, Miron A. Advance on the flavonoid cglycosides and health benefits. Crit Rev Food Sci Nutr. 2016;56(sup 1):S29–S45.
   PubMed Web of Science ®Google Scholar
• Knekt P, Järvinen R, Seppänen R, Hellövaara M, Teppo L, Pukkala E, Aromaa A. Dietary flavonoids and the risk of lung cancer and other malignant neoplasms. Am J Epidemiol. 1997;146(3):223–30. doi:10.1093/oxfordjournals.aje.a009257
   PubMed Web of Science ®Google Scholar
• Li S, Yu H, Ho CT. Nobiletin: efficient and large quantity isolation from orange peel extract. Biomed Chromatogr. 2006;20(1):133–8. doi:10.1002/bmc.540
   PubMed Web of Science ®Google Scholar
• Chen J, Creed A, Chen AY, Huang H, Li Z, Rankin GO, Ye X, Xu G, Chen YC. Nobiletin suppresses cell viability through AKT Pathways in PC-3 and DU-145 prostate cancer cells. BMC Pharmacol Toxicol. 2014;15:59. doi:10.1186/2050-6511-15-59
   PubMed Web of Science ®Google Scholar
• Deveci Ozkan A, Kaleli S, Onen HI, Sarihan M, Guney Eskiler G, Kalayci Yigin A, Akdogan M. Anti-inflammatory effects of nobiletin on TLR4/TRIF/IRF3 and TLR9/IRF7 signaling pathways in prostate cancer cells. Immunopharmacol Immunotoxicol. 2020;42(2):93–100. doi:10.1080/08923973.2020.1725040
   PubMed Web of Science ®Google Scholar
• Yoshimizu N, Otani Y, Saikawa Y, Kubota T, Yoshida M, Furukawa T, Kumai K, Kameyama K, Fujii M, Yano M, et al. Anti-tumour effects of nobiletin, a citrus fl avonoid, on gastric cancer include: antiproliferative effects, induction of apoptosis and cell cycle deregulation. Aliment Pharmacol Ther. 2004;20:95–101.
   PubMed Web of Science ®Google Scholar
• Shi MD, Liao YC, Shih YW, Tsai LY. Nobiletin attenuates metastasis via both ERK and PI3K/Akt pathways in HGF-treated liver cancer HepG2 cells. Phytomedicine. 2013;20(8-9):743–52. doi:10.1016/j.phymed.2013.02.004
   PubMed Web of Science ®Google Scholar
• Niu FW, Zhang YJ, Li K, Zhang MS. Nobiletin acts as a potential anticancer agent against osteosarcoma by regulating ERK and AKT signaling pathways. Bangladesh J Pharmacol. 2014;9(3):406–12.
   Web of Science ®Google Scholar
• Chen J, Chen AY, Huang H, Ye X, Rollyson WD, Perry HE, Brown KC, Rojanasakul YON, Rankin GO, Dasgupta P, et al. The flavonoid nobiletin inhibits tumor growth and angiogenesis of ovarian cancers via the Akt pathway. Int J Oncol. 2015;46(6):2629–38.
   PubMed Web of Science ®Google Scholar
• Sp N, Kang D, Joung Y, Park J, Kim W, Lee H, Song K-D, Park Y-M, Yang Y. Nobiletin inhibits angiogenesis by regulating Src/FAK/STAT3-mediated signaling through PXN in ER+ breast cancer cells cells. IJMS. 2017;18(5):935–2107.
   Web of Science ®Google Scholar
• Jiang YP, Guo H, Wang XB. Nobiletin (NOB) suppresses autophagic degradation via over-expressing AKT pathway and enhances apoptosis in multidrug-resistant SKOV3/TAX ovarian cancer cells. Biomed Pharmacother. 2018;103:29–37. doi:10.1016/j.biopha.2018.03.126
   PubMed Web of Science ®Google Scholar
• Zhao S, Zhang Y, Zhang Q, Wang F, Zhang D. Toll-like receptors and prostate cancer. Front Immunol. 2014;5:352. doi:10.3389/fimmu.2014.00352
   PubMed Web of Science ®Google Scholar